NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

18.90

USD

+0.01

+0.05%

Nov 06, 15:59 UTC -5

Closed

After-Market

18.85

-0.05

-0.26%

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Earnings

NAMS Earnings Reports

Positive Surprise Ratio

NAMS beat 6 of 12 last estimates.

50%

Next Report

Next Week

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$7.49M

-$0.51

Implied change from Q2 26 (Revenue/ EPS)

+102.29%

-1.92%

Implied change from Q3 25 (Revenue/ EPS)

+2051.42%

-16.39%

NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue

On Aug 05, 2026, NAMS reported earnings of -0.52 USD per share (EPS) for Q2 26, missing the estimate of -0.49 USD, resulting in a -4.44% surprise. Revenue reached 3.70 million, compared to an expected 1.70 million, with a 118.20% difference. The market reacted with a -0.47% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.51 USD, with revenue projected to reach 7.49 million USD, implying an decrease of -1.92% EPS, and increase of 102.29% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Guardian Pharmacy Services, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.30

Actual

$0.33

Surprise

+7.84%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.02

Actual

$0.06

Surprise

+144.90%

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Collegium Pharmaceutical, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.89

Actual

$1.96

Surprise

+3.17%

Ironwood Pharmaceuticals, Inc. - Class A

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.32

Actual

$0.36

Surprise

+9.16%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.32

Actual

-$0.36

Surprise

-11.15%

Profound Medical Corp. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.18

Actual

-$0.21

Surprise

-11.41%

Akebia Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.03

Actual

-$0.04

Surprise

-6.95%

FAQ

What were NewAmsterdam Pharma Company N.V. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.52, missing estimates by -4.44%, and revenue of $3.70M, 118.2% above expectations.

How did the market react to NewAmsterdam Pharma Company N.V. Ordinary Shares's Q2 2026 earnings?

The stock price moved down -0.47%, changed from $27.55 before the earnings release to $27.42 the day after.

When is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for NewAmsterdam Pharma Company N.V. Ordinary Shares's next earnings report?

Based on 9 analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.51 and revenue of $7.49M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.